Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 27, 2024, titled "Zydus and CSIR-Central Drug Research Institute Lucknow to develop best-in-class drug for Chronic Kidney Disease induced Osteoporosis".
Press Release Sep 27 2024
Filed with NSE · · 3 pages · English
Summary by 6ix AI
The partnership aims to create oral medications targeting Sclerostin, a protein linked to bone metabolism issues in CKD patients. This initiative highlights the urgent need for effective osteoporosis treatments that do not worsen kidney function. The collaboration combines Zydus's drug development expertise with CDRI's research capabilities to address significant health challenges.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Sep 13 2024
- Press Release Sep 10 2024
- Zydus receives final approval from USFDA for Scopolamine Transdermal System 1 mg/3 days
- Press Release Aug 30 2024
- Press Release Aug 27 2024
Later from Zydus Lifesciences
- Press Release Sep 28 2024
- Press Release Oct 01 2024
- Press Release Oct 02 2024
- Press Release Oct 10 2024
- Press Release Oct 14 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences